These findings show that xanthomas exhibit persistent metabolic activity despite short-term lipid lowering, whereas prolonged therapy may attenuate inflammation. Phenotypic differences underscore roles of disease stage, cumulative lipid exposure, and treatment duration. FDG-PET/CT provides metabolic information for risk assessment and therapeutic monitoring.
Nakayoshi et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: